Abstract
The following studies were carried out in pediatric patients.
1. Serum levels of PC-904 were examined in 3 patients by 1 hour intravenous infusion of 20mg/kg, reaching the peak of 22.5-25.5μg/ml at the end of infusion. Half life was 37-48 minutes.
2. Investigated in only 1 patient, the urinary excretion rate was 12.9% (0-6hours).
3. The effect of PC-904 on blood pressure was examined in 1 patient, and no effect was observed.
4. Clinical effects of PC-904 were examined in 9 patients; urinary tract infection (6 cases) and Salmonella enteritis (3 cases). The daily dose was 32.6-93.0mg/kg. The overall clinical effectiveness was 66.7%. As to causative organisms E.coli, Klebsiella and Salmonella were isolated. The clinical effects by the organisms were 100%, 0% and 66.7%, respectively.
5. Slight elevation of GOT and GPT and eosinophilia were observed in each one case but these abnormalities rapidly returned to pre-treatment levels when the administration was discontinued. No other side effects were noticed.
